Rinvoq 15 mg
Rinvoq 15 mg is a medicine authorised by Swissmedic under authorisation number 67257. The authorisation holder is AbbVie AG. The medicinal product code is Synthetic medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 20 January 2020 and the authorisation is valid without a time limit. ATC code L04AF03 places the medicine in the group Immunosuppressants.
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Rinvoq 15 mg, Retardtabletten | B | 20 January 2020 |
| 5 | Rinvoq 30 mg, Retardtabletten | B | 07 June 2024 |
| 6 | Rinvoq 45 mg, Retardtabletten | B | 07 June 2024 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 28 | Tablette(n) | L04AF03 | 07.15.0. | B |
| 3 | 28 | Tablette(n) | L04AF03 | 07.15.0. | B |
| 4 | 28 | Tablette(n) | L04AF03 | 07.15.0. | B |
Scroll the table sideways
Other medicines from this authorisation holder
Frequently asked questions
Is Rinvoq 15 mg authorised in Switzerland?
Yes. Rinvoq 15 mg is authorised by Swissmedic under authorisation number 67257, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does Rinvoq 15 mg have?
Rinvoq 15 mg is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of Rinvoq 15 mg?
The authorisation holder is AbbVie AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.